{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:38:26Z","timestamp":1762508306832},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der subakut kutane Lupus erythematodes (SCLE) ist ein Subtyp des kutanen Lupus erythematodes, der sich durch hohe Photosensitivit\u00e4t, Auftreten von anul\u00e4ren oder papulosquam\u00f6sen Hautver\u00e4nderungen im Bereich der UV-exponierten K\u00f6rperregionen, serologischen Nachweis von Anti-Ro\/SS-A-Antik\u00f6rpern und milde systemische Beteiligung wie Arthralgien und Myalgien auszeichnet. Wie bei anderen Formen des kutanen Lupus erythematodes kann auch der SCLE durch bestimmte Triggerfaktoren wie UV-Exposition, Zigarettenrauchen oder Medikamente ausgel\u00f6st werden. Rheumatische Erkrankungen wie die Dermatomyositis sind seit Langem als paraneoplastische Syndrome bekannt. In den letzten Jahren wird zunehmend \u00fcber die Assoziation von SCLE und Tumorerkrankungen publiziert. Wir berichten den Fall einer 78-j\u00e4hrigen Patientin, bei der zeitgleich mit der Entwicklung eines SCLE ein Magenkarzinom diagnostiziert wurde. Bei SCLE-Patienten h\u00f6heren Alters, ausgedehntem Befall au\u00dferhalb der UV-exponierten K\u00f6rperpartien oder neu aufgetretener B\u2011Symptomatik sollte das Vorliegen eines paraneoplastischen SCLE in Erw\u00e4gung gezogen und entsprechende diagnostische Schritte zur Abkl\u00e4rung einer Tumorerkrankung sollten eingeleitet werden.<\/jats:p>","DOI":"10.1007\/s00393-020-00926-9","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T17:03:29Z","timestamp":1606237409000},"page":"189-193","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Paraneoplastischer subakut kutaner Lupus erythematodes"],"prefix":"10.1007","volume":"80","author":[{"given":"R.","family":"Rezazadegan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Koushk-Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Oellig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tigges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"issue":"12","key":"926_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/archderm.1979.04010120007006","volume":"115","author":"RD Sontheimer","year":"1979","unstructured":"Sontheimer\u00a0RD, Thomas\u00a0JR, Gilliam\u00a0JN (1979) Subacute cutaneous lupus erythematodes: a\u00a0cutaneous marker for a\u00a0distinct lupus erythematosus subset. Arch Dermatol 115(12):1409\u20131415","journal-title":"Arch Dermatol"},{"key":"926_CR2","unstructured":"Worm\u00a0M et al (2020) S2k-Leitlinie \u201eDiagnostik und Therapie des kutanen Lupus erythematodes\u201c. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-060l_S2k_Kutaner_Lupus_erythematodes_2020-06.pdf. Zugegriffen: 10.09.2020"},{"issue":"6","key":"926_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1067\/mjd.2001.114565","volume":"44","author":"G Bonsmann","year":"2001","unstructured":"Bonsmann\u00a0G, Schiller\u00a0M, Luger\u00a0TA, St\u00e4nder\u00a0S (2001) Terbinafine-induced subacute cutaneous lupus erythematosus. J\u00a0Am Acad Dermatol 44(6):925\u2013931","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"926_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.autrev.2008.02.001","volume":"7","author":"V Racanelli","year":"2008","unstructured":"Racanelli\u00a0V, Prete\u00a0M, Minoia\u00a0C, Favoino\u00a0E, Perosa\u00a0F (2008) Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 7(5):352\u2013358","journal-title":"Autoimmun Rev"},{"key":"926_CR5","first-page":"181","volume":"40","author":"S Knispel","year":"2015","unstructured":"Knispel\u00a0S, Kirschke\u00a0J, Tigges\u00a0C, Hyun\u00a0J, Kreuter\u00a0A (2015) Paraneoplastischer oder medikamenteninduzierter subakut kutaner lupus erythematodes? Akt Dermatol 40:181\u2013183","journal-title":"Akt Dermatol"},{"issue":"5","key":"926_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jbspin.2016.09.010","volume":"84","author":"M Michel","year":"2017","unstructured":"Michel\u00a0M, Comoz\u00a0F, Ollivier\u00a0Y, Bienvenu\u00a0B (2017) First case of paraneoplastic subacute cutaneous lupus erythematosus associated with colon cancer. Joint Bone Spine 84(5):631\u2013633","journal-title":"Joint Bone Spine"},{"issue":"5","key":"926_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/ced.14176","volume":"45","author":"F Xie","year":"2020","unstructured":"Xie\u00a0F, Frewen\u00a0J, Divekar\u00a0P (2020) Three cases of subacute cutaneous lupus erythematosus associated Wirth malignancy: a\u00a0late paraneoplastic phenomenon. Clin Exp Dermatol 45(5):607\u2013608","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"926_CR8","first-page":"581","volume":"61","author":"A Kuhn","year":"1986","unstructured":"Kuhn\u00a0A, Kaufmann\u00a0I (1986) Subacute cutaneous lupus erythematosus as a\u00a0paraneoplastic syndrome. Z\u00a0Hautkr 61(8):581\u2013583","journal-title":"Z Hautkr"},{"issue":"2","key":"926_CR9","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jaad.2007.06.040","volume":"59","author":"W Weger","year":"2008","unstructured":"Weger\u00a0W, Kr\u00e4nke\u00a0B, Gerger\u00a0A, Salmhofer\u00a0W, Aberer\u00a0E (2008) Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine. J\u00a0Am Acad Dermatol 59(2):S4\u2013S6","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"926_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.annder.2011.02.015","volume":"138","author":"A Gantzer","year":"2011","unstructured":"Gantzer\u00a0A, Regnier\u00a0S, Cosnes\u00a0A et\u00a0al (2011) Subacute cutaneous lupus erythematosus and cancer: two cases and literature review. Ann Dermatol Venereol 138(5):409\u2013417","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"926_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/1346-8138.12281","volume":"40","author":"JH Ko","year":"2013","unstructured":"Ko\u00a0JH, Hsieh\u00a0CI, Chou\u00a0CY, Wang\u00a0KH (2013) Capecitabine-induced subacute cutaneous lupus erythematosus: report of a\u00a0case with positive rechallenge test. J\u00a0Dermatol 40(11):939\u2013940","journal-title":"J Dermatol"},{"issue":"11\u201312","key":"926_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00508-017-1201-3","volume":"129","author":"M Marovt","year":"2017","unstructured":"Marovt\u00a0M, Marko\u00a0PB (2017) Subacute cutaneous lupus erythematosus\u2014paraneoplastic to gastric adenocarcinoma? Wien Klin Wochenschr 129(11\u201312):444\u2013445","journal-title":"Wien Klin Wochenschr"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-020-00926-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T08:48:01Z","timestamp":1614761281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-020-00926-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00926-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"29 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Rezazadegan, B.\u00a0Koushk-Jalali, T.\u00a0Kuntz, F.\u00a0Oellig, C.\u00a0Tigges und A.\u00a0Kreuter geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}